Literature DB >> 17353238

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

A K Meagher1, J A Passarell, B B Cirincione, S A Van Wart, K Liolios, T Babinchak, E J Ellis-Grosse, P G Ambrose.   

Abstract

Exposure-response analyses were performed for the microbiological and clinical efficacy of tigecycline in the treatment of complicated skin and skin-structure infections, where Staphylococcus aureus and streptococci are the predominant pathogens. A prospective method was developed to create homogeneous patient populations for PK-PD analyses. Evaluable patients from three clinical trials were pooled for analysis. Patients received a tigecycline 100-mg loading dose/50 mg every 12 h or a 50-mg loading dose/25 mg every 12 h. At the test-of-cure visit, microbiologic and clinical responses were evaluated. Patients were prospectively evaluated and classified into cohorts based on baseline pathogens: S. aureus only (cohort 1), monomicrobial S. aureus or streptococci (cohort 2), two gram-positive pathogens (cohort 3), polymicrobial (cohort 4), or other monomicrobial infections (cohort 5). A prospective procedure for combining cohorts was used to increase the sample size. Logistic regression evaluated steady-state 24-h area under the concentration-time curve (AUC(24))/MIC ratio as a predictor of response, and classification and regression tree (CART) analyses were utilized to determine AUC/MIC breakpoints. Analysis began with pooled cohorts 2 and 3, the focus of these analyses, and included 35 patients with 40 S. aureus and/or streptococcal pathogens. CART analyses identified a significant AUC/MIC breakpoint of 17.9 (P = 0.0001 for microbiological response and P = 0.0376 for clinical response). The continuous AUC/MIC ratio was predictive of microbiological response based on sample size (P = 0.0563). Analysis of all pathogens combined decreased the ability to detect exposure-response relationships. The prospective approach of creating homogeneous populations based on S. aureus and streptococci pathogens was critical for identifying exposure-response relationships.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353238      PMCID: PMC1891381          DOI: 10.1128/AAC.01084-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?

Authors:  A MacGowan; C Rogers; K Bowker
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

2.  Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Authors:  S A Van Wart; J S Owen; E A Ludwig; A K Meagher; J M Korth-Bradley; B B Cirincione
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Letter: Creatinine clearance: bedside estimate.

Authors:  R W Jelliffe
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

4.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Soft tissue infections in parenteral drug abusers.

Authors:  G R Orangio; S D Pitlick; P Della Latta; L J Mandel; C Marino; J J Guarneri; J A Giron; I B Margolis
Journal:  Ann Surg       Date:  1984-01       Impact factor: 12.969

Review 6.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

7.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 8.  Foot infections in diabetic patients: the role of anaerobes.

Authors:  D N Gerding
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

9.  Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use.

Authors:  P H Summanen; D A Talan; C Strong; M McTeague; R Bennion; J E Thompson; M L Väisänen; G Moran; M Winer; S M Finegold
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  30 in total

1.  Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.

Authors:  Christopher M Rubino; Alan Forrest; Sujata M Bhavnani; Gary Dukart; Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.

Authors:  Catharine C Bulik; Dora E Wiskirchen; Ashley Shepard; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Jeffrey P Hammel; Alan Forrest; Nathalie Dartois; C Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

4.  Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.

Authors:  Paul G Ambrose; Jeffrey P Hammel; Sujata M Bhavnani; Christopher M Rubino; Evelyn J Ellis-Grosse; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

5.  Multi-drug-resistant Klebsiella pneumoniae pancreatitis: a new challenge in a serious surgical infection.

Authors:  Derin Tugal; Melanie Lynch; Andrea M Hujer; Susan Rudin; Federico Perez; Robert A Bonomo
Journal:  Surg Infect (Larchmt)       Date:  2014-05-21       Impact factor: 2.150

6.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 7.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

8.  Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.

Authors:  Julio Ramirez; Nathalie Dartois; Hassan Gandjini; Jean Li Yan; Joan Korth-Bradley; Paul C McGovern
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 9.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

10.  Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Authors:  J A Passarell; A K Meagher; K Liolios; B B Cirincione; S A Van Wart; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.